説明
Safety and toxicology considerations for probiotic-fermented herbal therapeutics in metabolic disease management. Adverse event profiles and drug interaction potential are reviewed from available clinical data.
Figure 19
DiagramSource Paper
Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insights into the Synergy of Probiotic-Fermented Herbal Bioactives.Cite This Figure
![Figure 19: Safety and toxicology considerations for probiotic-fermented herbal therapeutics in metabolic disease management. Adverse event profiles and drug interaction potential are reviewed from available clinical data.]() > Source: Yue Fan et al. "Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insigh." *International journal of molecular sciences*, 2025. PMID: [40564947](https://pubmed.ncbi.nlm.nih.gov/40564947/)
<figure> <img src="" alt="Safety and toxicology considerations for probiotic-fermented herbal therapeutics in metabolic disease management. Adverse event profiles and drug interaction potential are reviewed from available clinical data." /> <figcaption>Figure 19. Safety and toxicology considerations for probiotic-fermented herbal therapeutics in metabolic disease management. Adverse event profiles and drug interaction potential are reviewed from available clinical data.<br> Source: Yue Fan et al. "Gut Microbiota-Targeted Therapeutics for Metabolic Disorders: Mechanistic Insigh." <em>International journal of molecular sciences</em>, 2025. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40564947/">40564947</a></figcaption> </figure>